Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;25(10):3465-76.
doi: 10.1096/fj.11-186296. Epub 2011 Jun 29.

Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics

Lauren T May  1 , Lloyd J Bridge, Leigh A Stoddart, Stephen J Briddon, Stephen J Hill
Affiliations

Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics

Lauren T May et al. FASEB J. 2011 Oct.

Abstract

A growing awareness indicates that many G-protein-coupled receptors (GPCRs) exist as homodimers, but the extent of the cooperativity across the dimer interface has been largely unexplored. Here, measurement of the dissociation kinetics of a fluorescent agonist (ABA-X-BY630) from the human A(1) or A(3) adenosine receptors expressed in CHO-K1 cells has provided evidence for highly cooperative interactions between protomers of the A(3)-receptor dimer in single living cells. In the absence of competitive ligands, the dissociation rate constants of ABA-X-BY630 from A(1) and A(3) receptors were 1.45 ± 0.05 and 0.57 ± 0.07 min(-1), respectively. At the A(3) receptor, this could be markedly increased by both orthosteric agonists and antagonists [15-, 9-, and 19-fold for xanthine amine congener (XAC), 5'-(N-ethyl carboxamido)adenosine (NECA), and adenosine, respectively] and reduced by coexpression of a nonbinding (N250A) A(3)-receptor mutant. The changes in ABA-X-BY630 dissociation were much lower at the A(1) receptor (1.5-, 1.4-, and 1.5-fold). Analysis of the pEC(50) values of XAC, NECA, and adenosine for the ABA-X-BY630-occupied A(3)-receptor dimer yielded values of 6.0 ± 0.1, 5.9 ± 0.1, and 5.2 ± 0.1, respectively. This study provides new insight into the spatial and temporal specificity of drug action that can be provided by allosteric modulation across a GPCR homodimeric interface.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The 2-drug model of constitutive GPCR homodimerization. A) Within the 2-drug model of constitutive GPCR homodimerization, ligand A and ligand B can bind to the first and/or second protomer in the homodimer, R-R. Binding of ligand A and ligand B is defined by their affinity for the free GPCR homodimer, Ka and Kb, respectively, and the cooperativity factors α, β, and γ. B, C) Influence of γ = 1 (B) and γ = 0.001 (C) on the equilibrium binding properties A and B. D) Influence of γ = 0.01 on the dissociation of A in the presence of increasing concentrations of B. [Ligand B] = ● 0 nM, ○ 10 nM, ▴ 30 nM, ▵ 100 nM, ▾ 300 nM; ka+ = 5 × 107 M−1 s−1; ka− = 0.5 s−1; kb+ = 5 × 107 M−1 s−1; kb− = 0.5 s−1; α = 1; β = 1; Rtot = 1 × 10−9 M.
Figure 2.
Figure 2.
Cell surface A3-AR homomeric interactions. A) CHO cells transiently expressing A3-ARYFP. B) CHO cells transiently expressing A3-ARN-YFP and A3-ARC-YFP. Images are single confocal equatorial slices, representative of those obtained from 3 wells in each of 4 separate transfections.
Figure 3.
Figure 3.
Enhanced dissociation of a fluorescent adenosine derivative from the A3-AR in the presence of a competitive ligand. Binding of 30 nM ABA-X-BY630 to CHO-A3 cells after 0, 20 and 40 s of infinite dilution in the absence (A) or presence (B) of 1 μM XAC. Rate of perfusion was maintained at >12 complete fluid exchanges/min.
Figure 4.
Figure 4.
Competitive ligands significantly enhance the dissociation of 30 nM ABA-X-BY630 from the A3-AR. A–C) ABA-X-BY630 (30 nM) dissociation kinetics from CHO-A3 cells in the absence (●) or presence of XAC (A; ○ 10 nM, ▾ 100 nM, ▿ 1 μM, ▴ 10 μM); NECA (B; ○ 100 nM, ▾ 1 μM, ▿ 10 μM, ▴ 100 μM); or adenosine (C; ▾ 1 μM, ▿ 10 μM, ▴ 100 μM). D–F) ABA-X-BY630 (30 nM) dissociation kinetics from CHO-A1 cells in the absence (●) or presence (○) of XAC (D; 10 μM), NECA (E; 100 μM) or adenosine (F; 100 μM). Rate of perfusion was maintained at >12 complete fluid exchanges/min. Specific binding data was normalized as a percentage of fluorescent intensity at t =0 and globally analyzed according to a monophasic exponential decay. Data points are expressed as means ± se from 3–11 separate experiments; each replicate represents the average of 10 cells.
Figure 5.
Figure 5.
Concentration-koff relationship of ABA-X-BY630 dissociation in the absence and presence of competitive ligands at the A3-AR and A1-AR. Dissociation rate koff of 30 nM ABA-X-BY630 from CHO-A3 (A) and CHO-A1 cells (B) in the absence (□) or presence of XAC (■), NECA (○) and adenosine (●). Values for koff were derived from global analysis of dissociation kinetic data to a monophasic exponential decay.). Rate of perfusion was maintained at >12 complete fluid exchanges/min. Data points are expressed as means ± se from 3–11 separate experiments; each replicate represents the average of 10 cells.
Figure 6.
Figure 6.
Competitive ligands inhibit the binding of 30 nM ABA-X-BY630 to the A3-AR. A–C) ABA-X-BY630 (30 nM) association kinetics at CHO-A3 cells in the absence (●) or presence of XAC (A; ○ 10 nM, ▴ 100 nM, ▵ 1 μM); NECA (B; ○ 10 nM, ▴ 100 nM, ▵ 1 μM, ▾ 10 μM); or adenosine (C; ▵ 1 μM, ▴ 10 μM). D) ABA-X-BY630 (30 nM) specific binding at 2 min association in the presence of XAC (■), NECA (○) and adenosine (●). Rate of perfusion was maintained at >12 complete fluid exchanges/min. Data points are expressed as means ± se from 2 to 11 separate experiments; each replicate represents the average of 10 cells.
Figure 7.
Figure 7.
Cell surface expression of A3-AR fusions. Expression of A3-ARGFP (A; green channel) and A3(N250A)-ARYFP (B; red channel) in CHO cells. Images are single confocal equatorial slices.
Figure 8.
Figure 8.
Nonbinding A3(N250A)-AR can disrupt cooperative interactions between ABA-X-BY630 and NECA at the A3-AR. A) Expression of A3-ARGFP (green channel) and A3-ARYFP (red channel) in CHO cells. B, C) Influence of A3-ARGFP/A3-ARYFP fluorescence ratio (red, >10; blue, 1–9; black, 0.1–0.9) on dissociation of 30 nM ABA-X-BY630 in the absence (B) and presence (C) of 1 μM NECA. D) Dissociation rate of 30 nM ABA-X-BY630 in the absence (open bars) and presence (solid bars) of 1 μM NECA; cells are grouped according to their A3-ARGFP/A3-ARYFP fluorescence ratio. E) Expression of A3-ARGFP (green channel) and A3(N250A)-ARYFP (red channel) in CHO cells. F, G) Influence of A3-ARGFP/A3(N250A)-ARYFP fluorescence ratio (red, >10; blue, 1–9; black, 0.1–0.9) on dissociation of 30 nM ABA-X-BY630 in the absence (F) and presence (G) of 1 μM NECA. H) Dissociation rate of 30 nM ABA-X-BY630 in the absence (open bars) and presence (solid bars) of 1 μM NECA; cells are grouped according to their A3-ARGFP/A3(N250A)-ARYFP fluorescence ratio. Rate of perfusion was maintained at >12 complete fluid exchanges/min. Data points are expressed as means ± se from 5 to 38 cells from ≥3 separate experiments.
Figure 9.
Figure 9.
A kinetic 2-drug model of GPCR homodimerization can fit experimental data. Parameter estimation methods were applied to the kinetic 2-drug model of GPCR homodimerization fitting the association (A) and dissociation (B) of 30 nM ABA-X-BY630 in the presence of increasing concentrations of XAC and the association (C) and dissociation (D) of 30 nM ABA-X-BY630 in the presence of increasing concentrations of NECA. Data points are expressed as the mean from 3 to 11 separate experiments; each replicate represents the average of 10 cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bortolato A., Mobarec J. C., Provasi D., Filizola M. (2009) Progress in elucidating the structural and dynamic character of G protein-coupled receptor oligomers for use in drug discovery. Curr. Pharm. Des. 15, 4017–4025 - PMC - PubMed
    1. Overington J. P., Al-Lazikani B., Hopkins A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996 - PubMed
    1. Kenakin T., Onaran O. (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23, 275–280 - PubMed
    1. Birdsall N. J., Lazareno S. (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev. Med. Chem. 5, 523–543 - PubMed
    1. Christopoulos A. (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198–210 - PubMed

Publication types

Substances

LinkOut - more resources